Compare · ABT vs RGNT
ABT vs RGNT
Side-by-side comparison of Abbott Laboratories (ABT) and Regentis Biomaterials Ltd. (RGNT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ABT focuses on Biotechnology: Pharmaceutical Preparations, while RGNT focuses on Industrial Specialties.
- ABT is the larger of the two at $190.62B, about 19809.2x RGNT ($9.6M).
- ABT has been more active in the news (11 items in the past 4 weeks vs 2 for RGNT).
- ABT has more recent analyst coverage (25 ratings vs 0 for RGNT).
- Company
- Abbott Laboratories
- Regentis Biomaterials Ltd.
- Price
- -
- -
- Market cap
- $190.62B
- $9.6M
- 1M return
- +9.26%
- -
- 1Y return
- -13.02%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Industrial Specialties
- Exchange
- NYSE
- AMEX
- IPO
- 2025
- News (4w)
- 11
- 2
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
- Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
- Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
- Abbott Labs downgraded by Argus
- Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
- Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
- Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm
- SEC Form 8-K filed by Abbott Laboratories
- SEC Form 8-K filed by Abbott Laboratories
- Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
Latest RGNT
- SEC Form 6-K filed by Regentis Biomaterials Ltd.
- Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal
- Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City
- SEC Form EFFECT filed by Regentis Biomaterials Ltd.
- IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.
- SEC Form POS AM filed by Regentis Biomaterials Ltd.
- SEC Form 6-K filed by Regentis Biomaterials Ltd.
- Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
- SEC Form SCHEDULE 13G filed by Regentis Biomaterials Ltd.
- SEC Form S-8 filed by Regentis Biomaterials Ltd.